北京招聘

主要职责
微软操作系统（Windows 10/Windows7 ）支持，熟练掌握操作系统安装和相关配置。能快速排查用户电脑故障问题。
解决台式机、笔记本、打印一体机，会议设备MAXHUB和投影仪等设备的软硬件问题，能独立快速解决用户的软件及硬件问题。
了解IP电话、门禁系统的管理维护。
熟悉微软O365办公套件、VPN等办公软件的使用和维护，解决用户问题。
协助公司安全维护人员对用户的电脑进行系统漏洞升级及防护软件的日常更新。
熟悉TCP/IP、OSPF、BGP、802.1X、WLAN等网络协议，熟练掌握华为，H3C路由器、防火墙，交换机、无线AP等设备的配置和管理，包括日常维护和故障的排查。
定期对网络设备进行巡检，根据业务需求完成设备升级。
对IT资产做好相关登记和管理。
能独立完成领导交给的任务。




任职要求
本科及以上学历，计算机，信息类相关专业毕业。
有两年以上IT系统运维经验，有医药行业经验更佳。
熟练掌握windows，Linux系统，Office，Sharepiont等软件，能快速解决终端系统问题。
掌握华为，H3C网络知识，和防火墙，路由器，信息安全等基本知识。
快速学习，具备良好的职业道德与工作态度，善于沟通、工作踏实肯干。

    迪哲医药的前身为阿斯利康亚洲及新兴市场创新研发中心，设立于中国上海，是阿斯利康全球四个研发中心之一（另三个中心分别位于英国剑桥、瑞典哥德堡、美国盖瑟斯堡）；是国际一流、高产出的创新药研发机构，拥有全球领先的转化医学和新药分子设计与筛选技术平台；在恶性肿瘤、自身免疫性疾病、肾病等重大疾病的新药研究方面积累了丰富经验。
    迪哲医药，于2017年10月独立运营，是一家研发驱动型生物医药企业，致力于全球创新药物（First-in-class/ Best-in-class）探索、研发以及商业化。
    详情请点击公司官方网站：**************************/

Dizal Pharma
On Nov. 27th, 2017, through a joint venture between AstraZeneca and China Advanced Manufacturing Fund, Dizal Pharma was co-constructed as a world-leading innovative bio-pharmaceutical enterprise. As a new, unique mode of cooperation between SDIC Fund Management Company Ltd. and worldwide privileged research resources in the field of biological pharmacy, Dizal Pharma can not only accelerate the launch and listing of global new drugs in China, bring Chinese patients access to the latest drugs found across the world at once and thus raise the clinical benefits of patients; At the same time, we also take advantages of the global privileged innovative resources, increase China’s core competitive power in the innovation of new drugs, step in the leading branch of international research and development of new drugs and push China into the role of causing both huge and powerful influence in pharmacy industry.
As a new-style joint venture company, besides the project of the transfer of AstraZeneca’s patents, Dizal Pharma also develops the innovation and creation of global First-in-Class drugs.
The R&D (Research and Development) team of Dizal Pharma was AstraZeneca Asia and Emerging Market Research Center. As one of AstraZeneca’s first four R&D centers across the world, it dedicated to analyze the potential scientific mechanism of those most common diseases in Asia and fulfill the particular medical needs of Asian patients. It was one of the few R&D centers established by transnational pharmacy enterprises in China which had the ability to actually research, develop and produce micro-molecular new drugs, the ability to develop produce new drugs independently and completely, and the first-class medical platform in the world.